Lerisetron

Jump to: navigation, search
Lerisetron
Lerisetron.png
Clinical data
SynonymsLerisetron
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC18H20N4
Molar mass292.378 g/mol
 ☒N☑Y (what is this?)  (verify)

Overview

Lerisetron (F-0930-RS) is a drug which acts as an antagonist at the 5HT3 receptor[1] It is a potent antiemetic[2][3] and is currently in clinical trials for the treatment of nausea associated with cancer chemotherapy.[4]


References

  1. Orjales A, Mosquera R, Labeaga L, Rodes R. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation. Journal of Medicinal Chemistry. 1997 Feb 14;40(4):586-93. PMID 9046349
  2. Gomez-de-Segura IA, Grande AG, De Miguel E. Antiemetic effects of Lerisetron in radiation-induced emesis in the dog. Acta Oncologica. 1998;37(7-8):759-63. PMID 10050999
  3. Cooper M, Sologuren A, Valiente R, Smith J. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers. Arzneimittelforschung. 2002;52(9):689-94. PMID 12404884
  4. Huckle R. Lerisetron. FAES. Current Opinion in Investigational Drugs. 2003 Jul;4(7):874-7. PMID 14619411

Linked-in.jpg